Personalis (NASDAQ:PSNL) Shares Down 8.1% – What’s Next?

Personalis, Inc. (NASDAQ:PSNL) shares dropped 8.1% during trading on Thursday . The stock traded as low as $7.39 and last traded at $7.31. Approximately 302,397 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 1,349,796 shares. The stock had previously closed at $7.95.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Morgan Stanley reduced their target price on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Thursday, January 22nd. Needham & Company LLC boosted their price objective on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Guggenheim raised their target price on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Personalis Stock Performance

The company has a market capitalization of $703.11 million, a price-to-earnings ratio of -7.38 and a beta of 2.02. The business’s 50 day moving average is $8.81 and its 200 day moving average is $8.19.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. The business had revenue of $17.35 million during the quarter, compared to analysts’ expectations of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. Sell-side analysts predict that Personalis, Inc. will post -1.4 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the period. T. Rowe Price Investment Management Inc. raised its position in Personalis by 273.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after buying an additional 7,896,714 shares during the last quarter. Oracle Investment Management Inc. lifted its stake in Personalis by 47.9% during the 4th quarter. Oracle Investment Management Inc. now owns 339,343 shares of the company’s stock valued at $2,701,000 after acquiring an additional 109,908 shares during the period. First Manhattan CO. LLC. purchased a new stake in shares of Personalis in the 4th quarter valued at $2,976,000. Finally, Guggenheim Capital LLC acquired a new stake in shares of Personalis in the fourth quarter worth $108,000. 61.91% of the stock is owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.